SEARCH

SEARCH BY CITATION

References

  • Balfour D. J. (2009) The neuronal pathways mediating the behavioral and addictive properties of nicotine. Handb. Exp. Pharmacol. 192, 209233.
  • Benowitz N. L. (2010) Nicotine addiction. N. Engl. J. Med. 362, 22952303.
  • Benwell M. E. and Balfour D. J. (1997) Regional variation in the effects of nicotine on catecholamine overflow in rat brain. Eur. J. Pharmacol. 325, 1320.
  • Brunzell D. H. (2012) Preclinical evidence that activation of mesolimbic alpha 6 subunit containing nicotinic acetylcholine receptors supports nicotine addiction phenotype. Nicotine Tob. Res. 14, 12581269.
  • Cachope R., Mateo Y., Mathur B. N., Irving J., Wang H. L., Morales M., Lovinger D. M. and Cheer J. F. (2012) Selective activation of cholinergic interneurons enhances accumbal phasic dopamine release: setting the tone for reward processing. Cell Rep. 2, 3341.
  • Changeux J. P. (2010) Nicotine addiction and nicotinic receptors: lessons from genetically modified mice. Nat. Rev. Neurosci. 11, 389401.
  • Corrigall W. A., Franklin K. B., Coen K. M. and Clarke P. B. (1992) The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology 107, 285289.
  • Cragg S. J. (2003) Variable dopamine release probability and short-term plasticity between functional domains of the primate striatum. J. Neurosci. 23, 43784385.
  • Cragg S. J., Nicholson C., Kume-Kick J., Tao L. and Rice M. E. (2001) Dopamine-mediated volume transmission in midbrain is regulated by distinct extracellular geometry and uptake. J. Neurophysiol. 85, 17611771.
  • De Biasi M. and Dani J. A. (2011) Reward, addiction, withdrawal to nicotine. Annu. Rev. Neurosci. 34, 105130.
  • Dhelaria R. K., Friderici J., Wu K., Gupta E., Khan C. and Rothberg M. B. (2012) Effectiveness of varenicline for smoking cessation at 2 urban academic health centers. Eur. J. Intern. Med. 23, 461464.
  • Di Chiara G., Bassareo V., Fenu S. et al. (2004) Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology 47(Suppl 1), 227241.
  • Epping-Jordan M. P., Picciotto M. R., Changeux J. P. and Pich E. M. (1999) Assessment of nicotinic acetylcholine receptor subunit contributions to nicotine self-administration in mutant mice. Psychopharmacology 147, 2526.
  • Exley R. and Cragg S. J. (2008) Presynaptic nicotinic receptors: a dynamic and diverse cholinergic filter of striatal dopamine neurotransmission. Br. J. Pharmacol. 153(Suppl 1), S283S297.
  • Exley R., Clements M. A., Hartung H., McIntosh J. M. and Cragg S. J. (2008) Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology 33, 21582166.
  • Exley R., Maubourguet N., David V. et al. (2011) Distinct contributions of nicotinic acetylcholine receptor subunit alpha4 and subunit alpha6 to the reinforcing effects of nicotine. Proc. Natl Acad. Sci. USA 108, 75777582.
  • Gotti C., Guiducci S., Tedesco V. et al. (2010) Nicotinic acetylcholine receptors in the mesolimbic pathway: primary role of ventral tegmental area alpha6beta2* receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement. J. Neurosci. 30, 53115325.
  • Grace A. A. (2000) The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving. Addiction 95(Suppl 2), S119S128.
  • Grady S. R., Wageman C. R., Patzlaff N. E. and Marks M. J. (2012) Low concentrations of nicotine differentially desensitize nicotinic acetylcholine receptors that include alpha5 or alpha6 subunits and that mediate synaptosomal neurotransmitter release. Neuropharmacology 62, 19351943.
  • Hopkins T. J., Rupprecht L. E., Hayes M. R., Blendy J. A. and Schmidt H. D. (2012) Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats. Neuropsychopharmacology 37, 23102321.
  • Jackson K. J., McIntosh J. M., Brunzell D. H., Sanjakdar S. S. and Damaj M. I. (2009) The role of alpha6-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal. J. Pharmacol. Exp. Ther. 331, 547554.
  • Jarvik M. E., Madsen D. C., Olmstead R. E., Iwamoto-Schaap P. N., Elins J. L. and Benowitz N. L. (2000) Nicotine blood levels and subjective craving for cigarettes. Pharmacol. Biochem. Behav. 66, 553558.
  • John C. E., Budygin E. A., Mateo Y. and Jones S. R. (2006) Neurochemical characterization of the release and uptake of dopamine in ventral tegmental area and serotonin in substantia nigra of the mouse. J. Neurochem. 96, 267282.
  • Keating G. M. and Lyseng-Williamson K. A. (2010) Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation. Pharmacoeconomics 28, 231254.
  • Kuryatov A. and Lindstrom J. (2011) Expression of functional human alpha6beta2beta3* acetylcholine receptors in Xenopus laevis oocytes achieved through subunit chimeras and concatamers. Mol. Pharmacol. 79, 126140.
  • Liu L., Zhao-Shea R., McIntosh J. M., Gardner P. D. and Tapper A. R. (2012) Nicotine persistently activates ventral tegmental area dopaminergic neurons via nicotinic acetylcholine receptors containing alpha4 and alpha6 subunits. Mol. Pharmacol. 81, 541548.
  • Matta S. G., Balfour D. J., Benowitz N. L. et al. (2007) Guidelines on nicotine dose selection for in vivo research. Psychopharmacology 190, 269319.
  • Meyer E. L., Yoshikami D. and McIntosh J. M. (2008) The neuronal nicotinic acetylcholine receptors alpha4 and alpha6 differentially modulate dopamine release in mouse striatal slices. J. Neurochem. 105, 17611769.
  • Mills E. J., Wu P., Lockhart I., Thorlund K., Puhan M. and Ebbert J. O. (2012) Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: A systematic review and multiple treatment meta-analysis. Ann. Med. 44, 588597.
  • Paolini M. and De Biasi M. (2011) Mechanistic insights into nicotine withdrawal. Biochem. Pharmacol. 82, 9961007.
  • Perez X. A., Bordia T., McIntosh J. M., Grady S. R. and Quik M. (2008a) Long-term nicotine treatment differentially regulates striatal alpha6alpha4beta2* and alpha6(nonalpha4)beta2* nAChR expression and function. Mol. Pharmacol. 74, 844853.
  • Perez X. A., Parameswaran N., Huang L. Z., O'Leary K. T. and Quik M. (2008b) Pre-synaptic dopaminergic compensation after moderate nigrostriatal damage in non-human primates. J. Neurochem. 105, 18611872.
  • Perez X. A., O'Leary K. T., Parameswaran N., McIntosh J. M. and Quik M. (2009) Prominent role of alpha3/alpha6beta2* nAChRs in regulating evoked dopamine release in primate putamen: effect of long-term nicotine treatment. Mol. Pharmacol. 75, 938946.
  • Perez X. A., Bordia T., McIntosh J. M. and Quik M. (2010) alpha6ss2* and alpha4ss2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's disease. Mol. Pharmacol. 78, 971980.
  • Perez X. A., Ly J., McIntosh J. M. and Quik M. (2012) Long-term nicotine exposure depresses dopamine release in nonhuman primate nucleus accumbens. J. Pharmacol. Exp. Ther. 342, 335344.
  • Picciotto M. R., Zoli M., Rimondini R., Lena C., Marubio L. M., Pich E. M., Fuxe K. and Changeux J. P. (1998) Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391, 173177.
  • Pons S., Fattore L., Cossu G., Tolu S., Porcu E., McIntosh J. M., Changeux J. P., Maskos U. and Fratta W. (2008) Crucial role of alpha4 and alpha6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration. J. Neurosci. 28, 1231812327.
  • Quik M. and Wonnacott S. (2011) alpha6beta2* and alpha4beta2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease. Pharmacol. Rev. 63, 938966.
  • Quik M., Polonskaya Y., Gillespie A., K Lloyd G. and Langston J. W. (2000) Differential alterations in nicotinic receptor alpha6 and beta3 subunit messenger RNAs in monkey substantia nigra after nigrostriatal degeneration. Neuroscience, 100, 6372.
  • Quik M., Polonskaya Y., Kulak J. M. and McIntosh J. M. (2001) Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey. J. Neurosci. 21, 54945500.
  • Rice M. E. and Cragg S. J. (2004) Nicotine amplifies reward-related dopamine signals in striatum. Nat. Neurosci. 7, 583584.
  • Rice M. E., Patel J. C. and Cragg S. J. (2011) Dopamine release in the basal ganglia. Neuroscience 198, 112137.
  • Sellings L. H., Baharnouri G., McQuade L. E. and Clarke P. B. (2008) Rewarding and aversive effects of nicotine are segregated within the nucleus accumbens. Eur. J. Neurosci. 28, 342352.
  • Sofuoglu M. and Mooney M. (2009) Cholinergic functioning in stimulant addiction: implications for medications development. CNS Drugs 23, 939952.
  • Tapper A. R., McKinney S. L., Nashmi R. et al. (2004) Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science 306, 10291032.
  • Threlfell S., Lalic T., Platt N. J., Jennings K. A., Deisseroth K. and Cragg S. J. (2012) Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons. Neuron 75, 5864.
  • Tuesta L. M., Fowler C. D. and Kenny P. J. (2011) Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self-administration behavior. Biochem. Pharmacol. 82, 984995.
  • Wightman R. M. and Zimmerman J. B. (1990) Control of dopamine extracellular concentration in rat striatum by impulse flow and uptake. Brain Res. Brain Res. Rev. 15, 135144.
  • Wise R. A. (2009) Roles for nigrostriatal–not just mesocorticolimbic–dopamine in reward and addiction. Trends Neurosci. 32, 517524.
  • Yorgason J. T., Espana R. A. and Jones S. R. (2011) Demon Voltammetry and Analysis software: Analysis of cocaine-induced alterations in dopamine signaling using multiple kinetic measures. J. Neurosci. Methods 202, 158164.
  • Zhang H. and Sulzer D. (2004) Frequency-dependent modulation of dopamine release by nicotine. Nat. Neurosci. 7, 581582.
  • Zhang L., Zhou F. M. and Dani J. A. (2004) Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release. Mol. Pharmacol. 66, 538544.
  • Zhang L., Doyon W. M., Clark J. J., Phillips P. E. and Dani J. A. (2009a) Controls of tonic and phasic dopamine transmission in the dorsal and ventral striatum. Mol. Pharmacol. 76, 396404.
  • Zhang T., Zhang L., Liang Y., Siapas A. G., Zhou F. M. and Dani J. A. (2009b) Dopamine signaling differences in the nucleus accumbens and dorsal striatum exploited by nicotine. J. Neurosci. 29, 40354043.
  • Zhang L., Dong Y., Doyon W. M. and Dani J. A. (2011) Withdrawal from chronic nicotine exposure alters dopamine signaling dynamics in the nucleus accumbens. Biol. Psychiatry 71, 184191.
  • Zhao-Shea R., Liu L., Soll L. G. et al. (2011) Nicotine-mediated activation of dopaminergic neurons in distinct regions of the ventral tegmental area. Neuropsychopharmacology 36, 10211032.
  • Zhou F. M., Liang Y. and Dani J. A. (2001) Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat. Neurosci. 4, 12241229.
  • Zhu S. H., Lee M., Zhuang Y. L., Gamst A. and Wolfson T. (2012) Interventions to increase smoking cessation at the population level: how much progress has been made in the last two decades? Tob. Control 21, 110118.